Moderna (NASDAQ:MRNA) Stock Rating Upgraded by HSBC

Moderna (NASDAQ:MRNA) was upgraded by analysts at HSBC from a “hold” rating to a “buy” rating in a research report issued on Monday, MarketBeat.com reports. The brokerage presently has a $58.00 target price on the stock. HSBC’s target price would indicate a potential upside of 55.54% from the company’s previous close.

Other analysts have also recently issued research reports about the company. Leerink Partners lowered their price target on Moderna from $60.00 to $48.00 and set an “underperform” rating for the company in a research report on Tuesday, September 17th. Piper Sandler lowered their price target on Moderna from $157.00 to $115.00 and set an “overweight” rating for the company in a research report on Friday, September 13th. Wolfe Research initiated coverage on Moderna in a research note on Friday, November 15th. They set an “underperform” rating and a $40.00 price objective for the company. Sanford C. Bernstein initiated coverage on Moderna in a research note on Thursday, October 17th. They set a “market perform” rating and a $55.00 price objective for the company. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Friday, November 8th. Three investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $84.00.

Moderna Stock Down 5.6 %

Moderna stock opened at $37.29 on Monday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The stock has a market capitalization of $14.35 billion, a price-to-earnings ratio of -6.59 and a beta of 1.69. Moderna has a 1-year low of $35.80 and a 1-year high of $170.47. The business has a fifty day moving average price of $57.82 and a 200-day moving average price of $96.07.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. During the same quarter last year, the firm earned ($1.39) EPS. The business’s quarterly revenue was up 3.8% on a year-over-year basis. Equities research analysts forecast that Moderna will post -9.43 EPS for the current fiscal year.

Insider Transactions at Moderna

In related news, CFO James M. Mock sold 715 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now directly owns 9,505 shares in the company, valued at approximately $571,440.60. This represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 2,930 shares of company stock worth $217,170 in the last ninety days. Insiders own 15.20% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Moderna during the second quarter worth $26,000. Family Firm Inc. acquired a new position in Moderna in the second quarter valued at $33,000. Bank & Trust Co acquired a new stake in shares of Moderna during the second quarter worth about $36,000. Hanseatic Management Services Inc. acquired a new stake in shares of Moderna during the second quarter worth about $48,000. Finally, Plato Investment Management Ltd boosted its stake in shares of Moderna by 230.4% during the second quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock worth $49,000 after buying an additional 288 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.